Literature DB >> 18220595

Angiotensin II-induced signaling pathways in diabetes.

Mario B Marrero1, David Fulton, David Stepp, David M Stern.   

Abstract

Excessive cellular proliferation is a major contributor to the pathological changes associated with the secondary complications of diabetes. In particular, hyperglycemia (HG)-induced growth of vascular smooth muscle cells (VSMC) and glomerular mesangial cells (GMC) are characteristic features of the cardiovascular and renal complications of diabetes. VSMC and GMC respond to traditional growth factors, however in diabetes this occurs in the context of an environment, enriched in circulating vasoactive mediators and HG. For example, signaling via the angiotensin II (Ang II) pathway has been implicated in the pathogenesis of diabetic vascular disease. Recent findings indicate that HG and Ang II activate intracellular processes, including the polyol pathway and the generation of reactive oxygen species. These pathways activate the JAK (janus kinase)/STAT (signal transducers and activators of transcription) signaling cascades in both VSMC and GMC. Activation of the latter signaling cascade can stimulate excessive proliferation and growth of these cells, contributing to the accelerated atherosclerosis and nephropathy seen in the diabetic state. This review focuses on key factors in the diabetic microenvironment, in particular the interplay between HG, accumulation of advanced glycation end products and Ang II mediated signaling events both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18220595     DOI: 10.2174/1573399054022802

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  8 in total

1.  Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.

Authors:  Alia Shatanawi; Maritza J Romero; Jennifer A Iddings; Surabhi Chandra; Nagavedi S Umapathy; Alexander D Verin; Ruth B Caldwell; R William Caldwell
Journal:  Am J Physiol Cell Physiol       Date:  2011-02-02       Impact factor: 4.249

Review 2.  Epigenetic mechanisms in diabetic vascular complications.

Authors:  Marpadga A Reddy; Rama Natarajan
Journal:  Cardiovasc Res       Date:  2011-01-25       Impact factor: 10.787

3.  The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice.

Authors:  Kathryn E Husarek; Paige S Katz; Aaron J Trask; Maarten L Galantowicz; Mary J Cismowski; Pamela A Lucchesi
Journal:  Vascul Pharmacol       Date:  2015-06-30       Impact factor: 5.773

4.  A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.

Authors:  David S Hong; Razelle Kurzrock; Jeffrey G Supko; Xiaoying He; Aung Naing; Jennifer Wheler; Donald Lawrence; Joseph Paul Eder; Colin J Meyer; Deborah A Ferguson; James Mier; Marina Konopleva; Sergej Konoplev; Michael Andreeff; Donald Kufe; Hillard Lazarus; Geoffrey I Shapiro; Bruce J Dezube
Journal:  Clin Cancer Res       Date:  2012-05-25       Impact factor: 12.531

5.  Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.

Authors:  Scott A Reisman; Glenn M Chertow; Sudarshan Hebbar; Nosratola D Vaziri; Keith W Ward; Colin J Meyer
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

Review 6.  LncRNAs regulate ferroptosis to affect diabetes and its complications.

Authors:  Qianqian Chen; Hao Ji; Yue Lin; Zheyan Chen; Yinai Liu; Libo Jin; Renyi Peng
Journal:  Front Physiol       Date:  2022-09-26       Impact factor: 4.755

7.  The genetics of diabetic nephropathy.

Authors:  Eoin Brennan; Caitríona McEvoy; Denise Sadlier; Catherine Godson; Finian Martin
Journal:  Genes (Basel)       Date:  2013-11-05       Impact factor: 4.096

8.  AG490, a JAK2-specific inhibitor, downregulates the expression and activity of organic anion transporter-3.

Authors:  Jinghui Zhang; Chenchang Liu; Guofeng You
Journal:  J Pharmacol Sci       Date:  2018-02-08       Impact factor: 3.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.